欢迎登录材料期刊网

材料期刊网

高级检索

将介孔58S生物活性玻璃(m58S)作为抗癌药物载体评价了其对表阿霉素的装载量和释放性能.实验结果表明,m58S对亲水性药物表阿霉素的药物装载量为40%,是普通溶胶-凝胶58S生物活性玻璃的3倍多,并且具有更长效的缓释特性.研究还发现释放介质的pH值对表阿霉素的释放速率有很大影响,pH值越低,表阿霉素分子从载体材料中释放出的速率越快.因此,介孔生物活性玻璃是一种高效的药物缓释载体,且药物释放速率受释放介质pH值影响,有望成为药物控释型骨修复材料.

参考文献

[1] Wang T W,Wu H C,Wang W R,et al.The development of magnetic degradable DP-bioglass for hyperthermia cancer therapy.J.Biomed.Mater.Res.B,2007,83A:828-837.
[2] Geraci M,Birch J M,Alston R D,et al.Cancer mortality in 13 to 29-year-olds in England and Wales,1981-2005.Br.J.Cancer,2007,97:1588-1594.
[3] Schulman K L,Kohles J.Economic burden of metastatic bone disease in the US.Cancer,2007,109(11):2334-2342.
[4] Anderson P,Salazar-Abshire M.Improving outcomes in difficult bone cancers using multimodality therapy,including radiation:physician and nursing perspectives.Curr.Oncol.Rep.,2006,8(6):415-422.
[5] Arndt CAS,CristWM.Medicalprogress-common musculoskeletal tumors of childhood and adolescence.New.Eng.J.Med.,1999,341(5):342-352.
[6] Marina N,Gebhardt M,Teot L,et a/.Biology and therapeutic advances for pediatric osteosarcoma.Oncologist,2004,9(4):422-441.
[7] Sandberg A A,Bridge J A.Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors:osteosarcomaand related tumors.Cancer Genet.Cytogen.,2003,145(1):1-30.
[8] Bagi C M.Targeting of therapeutic agents to bone to treat metastaticcancer.Adv.Drug Delivery Rev.,2005,57(7):995-1010.
[9] Guise T A,Mundy G R.Cancer and bone.Endocr.Rev.,1998,19(1):18-54.
[10] Nagarajan R,Clohisy D R,Neglia J P,et al.Function and quality-of-life of survivors of pelvic and lower extremity osteosarcoma and Ewing's sarcoma:the childhood cancer survivor study.Br.J.Cancer,2004,91(11):1858-1865.
[11] Meyer J S,Mackenzie W.Malignant bone tumors and limb-salvage surgery in children.Pediatr.Radiol.,2004,34(8):606-613.
[12] Felder-Puig R,Formann A K,Mildner A,eta l.Quality of life andpsychosocial adjustment of young patients after treatment of bonecancer Cancer,1998,83(1):69-75.
[13] Serrano M C,Portoles M T,Pagani R,et al.In vitro positive biocompatibility evaluation of glass-glass ceramic thermoseeds for hyperthermic treatment of bone tumors.Tissue Eng.A,2008,14(5):617-627.
[14] Lindfors N C,Heikkila J T,Aho A J.Long-term evaluation of blood silicon and ostecalcin in operatively treated patients with benign bone tumors using bioactive glass and autogenous bone..L Biomed.Mater Res.B,2008,87B(1):73-76.
[15] Takegami K,Sano T,Wakabayashi H,et al.New ferromagnetic bone cement for local hyperthermia.J.Biomed.Mater Res.,1998,43(2):210-214.
[16] Hench L L.Bioceramics.J.Am.Ceram.Soc.,1998,81(7):1705-1728.
[17] Hench L L.Bioceramics-from concept to clinic.J.Am.Ceram.Soc.,1991,74(7):1487-1510.
[18] Yan X X,Yu C Z,Zhou X F,et al.Highly ordered mesoporous bioactive glasses with superior in vitro bone-forming bioactivities.Angew.Chem.Int.Ed,2004,43(44):5980-5984.
[19] Xia W,Chang J.Well-ordered mesoporous bioactive glasses (MBG):A promising bioactive drug delivery system.J.Controlled Release,2006,110(3):522-530.
[20] Xia W,Chang J,Lin J P,et al.The pH-controlled dual-drug release from mesoporous bioactive glass/polypeptide graft copolymer nanomicelle composites.Eur J.Pharm.Biopharm,2008,69(2):546-552.
[21] Xia W,Chang J.Preparation,in vitro bioactivity and drug release property of well-ordered mesoporous 58S bioactive glass.J.Non-Cryst.Solids,2008,354(12/13):1338-1341.
[22] Kumar D,Tomar R S,Deolia S K,et al.Isolation and characterizationofdegradationimpuritiesinepirubicin hydrochloride injection.J.Chromatogr B,2008,869(1/2):45-53.
[23] Ozdemir F A,Anilanmert B,Pekin M.Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCI and epimbicin-HCI in the same infusion solution.Cancer Chemoth.Pharm,2005,56(5):529-534.
[24] Kelso E J,Geraghty R F,McDermott B J,et al.Characterisation of a cellular model of cardiomyopathy,in the rabbit,produced by chronic administration of the anthracycline,epirubicin.J.Mol.Cell Cardiol.,1997,29(12):3385-3397.
[25] Masuda N,Amani S,Nishikata M,et al.Appropriate solution selection at the administering epirubicin hydrochloride to the breast cancer patients.European Journal of Cancer Supplements,2004,2(3):145.
[26] Nielsen O S,Dombemowsky P,Mouridsen H,et al.High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas.a study of the EORTC soft tissue and bone sarcoma group.Br.J.Cancer,1998,78(12):1634-1639.
[27] 刘勤江,田尤新,肖忆南.阿霉素在肿瘤局部化疗中的应用研究.肿瘤学杂志,2004,10(1):45-47.
[28] Oonishi H,Kushitani S,Yasukawa E,et al.Particulate bioglass compared with hydroxyapatite as a bone graft substitute.Clin.Orthop.Relat.Res.,1997,334:316-325.
[29] Oonishi H,Hench L L,Wilson J,et al.Comparative bone growth behavior in granules of bioceramic materials of various sizes.J.Biomed.Mater Res.,1999,44(1):31-43.
[30] Zhong J P,Greenspan D C.Processing and properties of Sol-Gel bioactive glasses.J.Biomed.Mater.Res.,2000,53(6):694-701.
[31] Chen Q Z,Ahmed I,Knowles J C,et al.Collagen release kinetics of surface functionalized 4555 Bioglass(R)-based porous scaffolds.J.Biomed.Mater Res.A,2008,86A(4):987-995.
[32] Erdinc N,Gokturk S,Tuncay W.Interaction ofepirubicin HCl with surfactants:effect of NaCl and glucose.J.Pharm.Sci.,2004,93(6):1566-1576.
[33] Li X,Zhang L X,Dong X P,et al.Preparation of mesoporous calcium doped silica spheres with narrow size dispersion and their drug loading and degradation behavior.Microporous.Mesoporous.Mater,2007,102(1/2/3):151-158.
[34] Zhao D Y,Feng J L,Huo Q S,et al.Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores.Science,1998,279(5350):548-552.
[35] Guo M,Yan Y,Zhang H K,et al.Magnetic and pH-responsive nanocarriers with multilayer core-shell architecture of anticancer drug delivery.J.Mater Chem.,2008,18(42):5104-5112.
[36] Pal R,Kundu D.Sol-Gel synthesis of porous and dense silica microspheres.J.Non-Cryst.Solids,2009,355(1):76-78.
上一张 下一张
上一张 下一张
计量
  • 下载量()
  • 访问量()
文章评分
  • 您的评分:
  • 1
    0%
  • 2
    0%
  • 3
    0%
  • 4
    0%
  • 5
    0%